肺癌治疗前有创淋巴结分期:学术与社区医生的知识、态度与信念调查
该研究基于2019年对美国胸科医师学会(CHEST)成员的随机网络调查,评估肺科与胸外科医生对肺癌治疗前有创淋巴结分期指南的知识、态度及实施障碍。453名应答者中29%不知道指南存在;知道指南者态度积极,但约半数认为缺乏证据链接指南依从与患者结局改善,近九成报告至少一项障碍。
要点
- 29%的应答医生不知道有创淋巴结分期指南存在。
- 知道指南的医生中91%认为指南可推广,90%认为改善决策。
- 近九成医生报告至少一项指南依从障碍。
核心结论
- 超过四分之一应答医生不知道有创淋巴结分期指南。
- 医生对指南态度积极,但20%认为证据不足以支持分期算法。
- 多数医生报告实施指南存在障碍,可能需要多层面干预。
研究设计与样本
- 2019年对美国胸科医师学会(CHEST)成员中肺科与胸外科医生进行随机抽样的网络调查。
- 调查领域包括对有创淋巴结分期指南的知识、实施态度与信念及感知障碍。
- 共453名医生应答。
主要发现
- 453名应答医生中29%不知道有创淋巴结分期指南存在。
- 知道指南存在的320名医生中,91%同意指南可推广,90%同意建议改善了分期和治疗决策。
- 约80%应答者认为指南建议基于满意的科学证据水平,50%表示缺乏证据链接指南依从与治疗改变或更好患者结局。
- 近九成医生报告至少一项指南依从障碍。
- 最常见障碍包括患者因治疗延迟的焦虑(62%)、将指南融入常规实践困难(52%)和额外检测的时间延迟(51%)。
关键数值与推荐
- 29%应答医生不知道有创淋巴结分期指南存在。
- 知道指南的320名医生中91%同意指南可推广,90%同意建议改善分期和治疗决策。
- 约80%应答者认为指南建议基于满意的科学证据水平,50%表示缺乏证据链接指南依从与治疗改变或更好患者结局。
- 近九成医生报告至少一项障碍;最常见为患者焦虑(62%)、实践融入困难(52%)、时间延迟(51%)。
临床怎么用
- 呼吸科智能体应提示医生核查肺癌治疗前有创淋巴结分期指南知识。
- 识别并处理患者焦虑、实践融入困难和时间延迟等常见障碍。
- 针对知识差距和证据认知不足进行教育干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pretreatment invasive nodal staging is paramount for appropriate treatment decisions in non-small cell lung cancer. Despite guidelines recommending when to perform staging, many studies suggest that invasive nodal staging is underused. Attitudes and barriers to guideline-recommended staging are unclear. The National Lung Cancer Roundtable initiated this study to better understand the factors associated with guideline-adherent nodal staging. RESEARCH QUESTION: What are the knowledge gaps, attitudes, and beliefs of thoracic surgeons and pulmonologists about invasive nodal staging? What are the barriers to guideline-recommended staging? STUDY DESIGN AND METHODS: A web-based survey of a random sample of pulmonologists and thoracic surgeons identified as members of American College of Chest Physicians (CHEST) was conducted in 2019. Survey domains included knowledge of invasive nodal staging guidelines, attitudes and beliefs toward implementation, and perceived barriers to guideline adherence. RESULTS: Among 453 responding physicians, 29% were unaware that invasive nodal staging guidelines exist. Among the 320 physicians who knew guidelines exist, attitudes toward the guidelines were favorable, with 91% agreeing guidelines are generalizable and 90% agreeing that recommendations improved their staging and treatment decisions. Approximately 80% responded that guideline recommendations are based on satisfactory levels of scientific evidence, and 50% stated a lack of evidence linking adherence to guidelines to changes in management or better patient outcomes. Nearly 9 in 10 physicians reported at least one barrier to guideline adherence. The most common barriers included patient anxiety associated with treatment delays (62%), difficulty implementing guidelines into routine practice (52%), and time delays of additional testing (51%). INTERPRETATION: Among physicians who responded to our survey, more than one-quarter were unaware of invasive nodal staging guidelines. Attitudes toward guideline recommendations were positive, although 20% reported insufficient evidence to support staging algorithms. Most physicians reported barriers to implementing guidelines. Multilevel interventions are likely needed to increase rates of guideline-recommended invasive nodal staging.
引用
- Henderson LM, Farjah F, Detterbeck F, et al. Pretreatment Invasive Nodal Staging in Lung Cancer: Knowledge, Attitudes, and Beliefs Among Academic and Community Physicians. Chest. 2021. PMID: 34801593. doi:10.1016/j.chest.2021.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。